iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.
Xiaohui GuoWenying YangJunqing ZhangXiaolin DongMing LiuShenghong GuFelipe LauandLingyu LiQiong HuangLei KangElisabeth SouhamiPublished in: Diabetes, obesity & metabolism (2023)
iGlarLixi achieved greater improvements in dTIR parameters vs. iGlar or Lixi in insulin-naïve and insulin-experienced AP people with T2D. This article is protected by copyright. All rights reserved.